Amneal Pharmaceuticals, Inc.
AMRX
$11.94
-$0.18-1.49%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 3.80% | 8.28% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.80% | 8.28% | |||
| Cost of Revenue | 5.78% | 11.34% | |||
| Gross Profit | 0.50% | 3.55% | |||
| SG&A Expenses | 6.29% | 10.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 99.15% | -- | |||
| Total Operating Expenses | 1.24% | 12.86% | |||
| Operating Income | 22.76% | -16.73% | |||
| Income Before Tax | 1,157.53% | -110.10% | |||
| Income Tax Expenses | 124.24% | -245.05% | |||
| Earnings from Continuing Operations | 173.40% | -49.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 8.03% | -19.48% | |||
| Net Income | 1,380.62% | -89.43% | |||
| EBIT | 22.76% | -16.73% | |||
| EBITDA | 11.12% | -14.39% | |||
| EPS Basic | 1,386.67% | -89.51% | |||
| Normalized Basic EPS | 44.73% | -23.79% | |||
| EPS Diluted | 1,357.33% | -89.29% | |||
| Normalized Diluted EPS | 43.14% | -24.26% | |||
| Average Basic Shares Outstanding | 0.09% | 0.14% | |||
| Average Diluted Shares Outstanding | 1.03% | 0.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||